Novo Nordisk ® h dose oral sema hold potential to nt intensification to target Phase 3 trial with oral semaglutide 25 mg and 50 mg in T2D has been initiated Semaglutide 50 mg Semaglutide 25 mg Semaglutide 14 mg Dose escalation Maintenance Primary endpoint after 52 weeks 68 weeks on-treatment 5-weeks Follow-up Objective • Trial will assess efficacy for patients in need of improved outcomes Primary endpoint • Confirm superiority of semaglutide 25 mg and 50 mg once-daily versus oral semaglutide 14 mg on HbA 1c reduction
Download PDF file